A new round of health care negotiations is like an arrow! Of the 490 medicines, 344 passed the preliminary form examination

【Pharmaceutical Network Industry News】On September 6, the National Medical Insurance Bureau has announced the list of drugs that have passed the preliminary form review in the adjustment of the national medical insurance drug list in 2022, and 344 of the 490 declared drugs have passed the preliminary form review
.

Compared with 2021 (271 of the 474 drugs passed), the number of drugs declared and passed the preliminary form examination has increased
.

The adjustment of the medical insurance drug catalogue is divided into enterprise declaration, formal review, expert review, negotiation and bidding and other links
.

Among them, the preliminary form review is a preliminary review of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug list in that year and the integrity of drug information
.

Passing the formality check means that the drug is eligible for the next stage of review
.

In accordance with the Interim Measures for the Administration of Drugs in Basic Medical Insurance and the Work Plan for adjusting the Catalogue of Drugs for National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance in 2022 (hereinafter referred to as the Work Plan), the review method and review process will be changed this year, further optimizing the content of enterprise declarations and enriching the requirements for drug submission information in the declaration materials, including effectiveness, safety, economy, innovation and fairness, etc.
And give enterprises more opportunities to introduce their own varieties
.

In the 2021 medical insurance directory, some drugs of up to one million yuan have been successfully included in medical insurance, which has aroused the attention of the industry and ignited the hope
of many patients.

For example, the drug "Northinalsan Sodium Injection" developed by Bojian for the treatment of SMA rare disease (spinal muscular dystrophy), which was initially sold for nearly 700,000 yuan in China, was sold for nearly 700,000 yuan in a single bottle at the beginning of the market, and after medical insurance negotiations in 2021, the price dropped to about
33,000 yuan per bottle.

Another example is the drug agasaclycase for the treatment of Fabrai disease α a concentrated solution for injection, the drug has previously cost more than one million yuan, and it only costs a few thousand yuan to take a drug after entering the medical insurance directory, which greatly reduces the cost burden of
patients.

It is understood that some of the more expensive drugs this year have passed the preliminary formal examination
.

However, the industry said that whether this drug can successfully enter the medical insurance list in the end still needs to be strictly evaluated in many aspects, including economy, and only successful negotiations or bidding can be included in the directory
.

In addition, innovative drugs into medical insurance has also attracted much attention in the industry, the National Medical Insurance Bureau said in a reply a few days ago, the National Medical Insurance Bureau to innovative drugs into the medical insurance drug catalog to support and tilt, medical insurance drug catalog access scope focus on listed new drugs, the catalog is normalized every year, some innovative drugs are included in the national medical insurance catalog in the same year, quickly introduced to the market
.

Since its establishment in 2018, the National Medical Insurance Bureau has included 507 new drugs and good drugs in four years, and the scope of drug treatment has gradually covered the fields of tumors, chronic diseases, rare diseases and children's drugs, bringing the gospel
to more patients.

At the same time, 391 drugs with inaccurate efficacy were transferred, and the current version of the medical insurance catalogue increased to 2860 kinds of Western medicines and proprietary Chinese medicines
.

In addition, 250 drugs were included in medical insurance through price negotiations, with an average price reduction of more than 50%.
It is reported that in the future, the National Medical Insurance Bureau will continue to improve the adjustment mechanism of the medical insurance drug list, comprehensively consider the balanced development of the direction of drug innovation and the drug demand of the insured and the affordability of the medical insurance fund, and carry out the directory negotiation and access work more scientifically and reasonably, so as to improve the protection level
of the majority of insured patients.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.